Related Experiment Video
Updated: Jun 21, 2026
Immunofluorescence Imaging of DNA Damage and Repair Foci in Human Colon Cancer Cells
Published on: June 9, 2020
Interaction of ionizing radiation and ZRBA1, a mixed EGFR/DNA-targeting molecule
Mitra Heravi1, Zakaria Rachid, Atta Goudarzi
1Department of Human Genetics, Cancer Drug Research Laboratory, McGill University, Montreal, Quebec H3T 1E2, Canada.
Abstract:
ZRBA1 is a molecule termed 'combi-molecule' designed to induce DNA-alkylating lesions and to block epidermal growth factor receptor (EGFR) tyrosine kinase. Owing to its ability to downregulate the EGFR tyrosine kinase-mediated antiapoptotic signaling and DNA repair proteins, we inferred that it could significantly sensitize cells to ionizing radiation. Using the MDA-MB-468 human breast cancer cell line in which ZRBA1 has already been reported to induce significant EGFR/DNA-targeting potency, the results showed that: (i) concurrent administration of ZRBA1 and 4 Gy radiation led to a significant decrease in cell viability, (ii) the greater efficacy of the combination was sequential, being limited to conditions wherein the drug was administered concurrently with radiation or before radiation, and (iii) the efficacy enhancement of the combination was further confirmed by clonogenic assays from which a dose enhancement factor of 1.34 could be observed at survival fraction of 0.01. Flow cytometric analysis showed significant enhancement of cell cycle arrest in G2/M (P<0.046, irradiated cells vs. cells treated with ZRBA1 and radiation) and increased apoptosis when ZRBA1 was combined with radiation. Likewise, significant levels of double-strand breaks were observed for the combination, as determined by neutral comet assay (P<0.045, irradiated cells vs. cells treated with ZRBA1 and radiation). These results in toto suggest that the superior efficacy of the ZRBA1 plus radiation combination may be secondary to the ability of ZRBA1 to arrest the cells in G2/M, a cell cycle phase in which tumor cells are sensitive to radiation. Furthermore, the increased levels of DNA damage, combined with the concomitant downregulation of EGFR-mediated signaling by ZRBA1, may account for the significant levels of cell killing induced by the combination.
Insights
ZRBA1 enhances radiation therapy for breast cancer by inducing DNA damage and blocking EGFR signaling, leading to increased cell death. This combination therapy shows superior efficacy when ZRBA1 is administered before or during radiation treatment.
Area of Science:
- Oncology
- Radiation Oncology
- Molecular Biology
Background:
- ZRBA1 is a novel 'combi-molecule' designed to induce DNA-alkylating lesions and inhibit epidermal growth factor receptor (EGFR) tyrosine kinase.
- EGFR signaling plays a crucial role in cell survival and DNA repair, making it a potential target for cancer therapy.
- ZRBA1's ability to downregulate antiapoptotic and DNA repair proteins suggests its potential to sensitize cancer cells to radiation.
Purpose of the Study:
- To investigate the efficacy of ZRBA1 in combination with ionizing radiation in the MDA-MB-468 human breast cancer cell line.
- To determine the optimal administration sequence of ZRBA1 and radiation for enhanced anti-cancer effects.
- To elucidate the underlying mechanisms of ZRBA1-radiation synergy, including cell cycle effects, apoptosis induction, and DNA damage.
Main Methods:
- Cell viability assays were performed following concurrent administration of ZRBA1 and 4 Gy radiation.
- Clonogenic assays were utilized to assess the dose enhancement factor of the combination therapy.
- Flow cytometry was employed to analyze cell cycle distribution and apoptosis.
- Neutral comet assays were conducted to quantify DNA double-strand breaks.
Main Results:
- Concurrent administration of ZRBA1 and radiation significantly decreased MDA-MB-468 cell viability.
- The combination therapy demonstrated greater efficacy when ZRBA1 was administered concurrently with or prior to radiation.
- Clonogenic assays revealed a dose enhancement factor of 1.34 at a survival fraction of 0.01.
- Flow cytometry indicated enhanced G2/M cell cycle arrest and increased apoptosis in combination-treated cells.
- Neutral comet assays showed significantly elevated levels of DNA double-strand breaks in cells treated with the combination.
Conclusions:
- ZRBA1 significantly enhances the efficacy of ionizing radiation in MDA-MB-468 breast cancer cells.
- The synergistic effect is attributed to ZRBA1-induced G2/M cell cycle arrest, increased apoptosis, and enhanced DNA damage.
- Downregulation of EGFR-mediated signaling by ZRBA1 contributes to the potentiation of radiation-induced cell killing.
- Sequential administration, with ZRBA1 given before or during radiation, maximizes the therapeutic benefit.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:38Mitogens and the Cell Cycle
01:38Nucleotide Excision Repair
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...
01:08Nucleotide Excision Repair
01:18Other Unique Bacteria
01:35Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...